Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
By P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, L. Rivoltini. Journal of Clinical Oncology, 2007
704 citations recorded by the source corpus.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/bb5c8eb7f7b943539342b4b5714a0401752a4ad1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- D. Gabrilovich
- S. Ostrand-Rosenberg
- V. Bronte
- P. Sinha
- P. Serafini
- Paola Zanovello
- L. Dolcetti
- Ilaria Marigo
Citations in the corpus
- Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells (2008, background): “An increase in blood CD11b(1)/CD14(1) cells affecting T-cell proliferation and effector functions was detected recently in patients with metastatic melanoma (36).”
- Coordinated regulation of myeloid cells by tumours (2012, background): “, whereas CD14 + CD11b + HLA-DR low/− monocytic MDSCs circulate in the blood of patients with melanoma, multiple myeloma, prostate cancer, hepatocellular carcinoma or head and neck cance”
- The tumor microenvironment and its role in promoting tumor growth (2008, background): “A recent report describes expansion of CD14þHLA-DR /low myeloid-derived cells exerting immune suppression through TGF-b production in the peripheral circulation of patients with metastatic melanoma treated with GM-CSF-based vaccines Oncogene (Filipazzi et al., 2007).”
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer (2009, background): “In cancer patients MDSC are typically CD11b CD33 CD34 CD14 HLA-DR and can vary in their expression of CD15 and other markers (30, 33, 47, 48).”
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (2008, background): “Therefore, as an immunomodulatory agent, cyclophosphamide should be used with caution just as was recently reported with GM-CSF [11].”
- Myeloid-derived suppressor cell heterogeneity and subset definition. (2010, background): “In partial contrast with these findings, MDSCs were recently identified in the monocyte fraction of melanoma patients by the markers CD14/CD11b/HLA-DR and secretion of TGF-b, which was recognized as a mediator of the immune suppression [36].”